Immusoft Receives $4M in Funding from the California Institute for Regenerative Medicine (CIRM)

Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support the development of its ISP-002 (for delivery of iduronate sulfatase) program in mucopolysaccharidosis type II (MPS II), an inherited disease for which patients have limited options. MPS II is a rare genetic disease in children, which causes abnormalities across many organs, including the heart and lungs, and the musculoskeletal system. Read more >>